News and Events

Stay up to date with Cypre’s latest conference presentations, publications, and company updates.

News

Blogs

2026 AACR

Cypre attended the annual American Association of Cancer Research Conference in San Diego, meeting with partners and reviewing the latest trends in oncology therapeutic research. Next gen modalities like bispecific antibodies, ADCs, and in vivo cell therapies are advancing in pharma pipelines for their differentiated mechanism, reduced toxicity, and enhanced efficacy.

Blogs

2026 JPM Conference

Cypre met with key leaders of the biopharmaceutical and life science industry on January 12-15. With the FDA's shift away from animal testing, there is considerable momentum to implement organoid and AI-driven approaches in drug discovery and safety assessment to advance the next generation of therapeutics.

Blogs

2025 BIO Partnering Conference

Cypre was excited to attend this year's BIO Partnering Conference in Boston this June, the pre-eminent meeting for strategic discussions and deal-making in the biotechnology industry. Despite the macro challenges facing the market, partnering remains a core strategy for companies large and small to achieve our ultimate end goal - patient success.

Featured Resources

2025 AACR

At AACR this year, we debuted new datasets on NK cell therapy screening and MOA assessment on the Cypre Tumor Organoid Platform. Post-FDA's announcement, organoids and AI-enabled platforms were a highlight at the conference for Cypre, among an abundance of therapeutic data and precision medicine initiatives.

Blogs

2025 JPM Healthcare Conference

Cypre's CEO, Kolin Hribar, PhD, was taking meetings with partners to advance the next generation of cancer therapeutics. Interested parties were encouraged to reach out to schedule a meeting.

Featured Resources

2024 Antibody Engineering & Therapeutics

We are excited to share the latest data on screening checkpoint inhibitors (anti-PD1, anti-CTLA4), and a T cell engager (anti-CD3, anti-EpCAM), revealing their mechanism of action in the Cypre tumor microenvironment organoids and the data’s implications for cytokine release syndrome.

Featured Resources

2024 AACR Poster

Cypre presented its poster at AACR24: “Automated 42 PDX 3D in vitro tumor models of the TME screen immuno-oncology and targeted compounds and biologics for antitumor effects and MOA” on Tuesday, April 9th at 9am-noon in Section 28 (Poster 23, Abstract 4703).

Blogs

Eureka Blog Post

November 30, 2023: Cypre Founder and CEO, Kolin Hribar, PhD, is interviewed by the Eureka Blog to discuss revolutionizing oncology drug development with translationally relevant 3D tumor models.

Blogs

Q2 2023 Press Release

Cypre announces its 3D in vitro tumor models services and landmark publication detailing the platform for screening targeted and immunotherapy compounds and assessing novel immuno-modulatory insights.

Resources

Q1 2023 Press Release

Charles River launches press release ahead of AACR for its end-to-end Oncology Discovery capabilities, with the Cypre platform featured as a critical step for in vitro pharmacology and drug screening prior to IND.

Resources

2022 SITC Posters

Cypre presents posters at the Society for Immunotherapy Conference (SITC) titled “#299 3D in vitro Tumor microenvironment models for screening CAR-T cell therapy efficacy.” , “#1447 A 30 PDX Panel of 3D in vitro tumor models identifies responders”

Resources

2022 AACR Poster

Cypre presented a joint poster with Charles River at AACR titled “#1880 - High throughput screening of 30 PDX cell lines in a 3D ECM hydrogel platform, incorporating tumor, stroma and immune components to demonstrate simultaneous investigation of multiple anti-tumor modalities”, highlighting the 3D Tumor Model Platform in screening 30 PDX models simulatenously with both small molecules and antibodies.

Resources

2021 AACR Poster

Cypre presented a joint poster with Charles River at AACR titled “3184 - 3D in vitro tumor model platform for screening patient-derived NSCLC, CRC, and RCC tumors with targeted therapy and immunotherapy”, highlighting the 3D Tumor Model Platform in screening PDX models with both small molecules and antibodies.

Upcoming Events

Quick links
Platform
Our Team
Contact
About
Company
Resources & Publications
News & Events
Office:
135 Mississippi Street
San Francisco, CA, 94107
United States
© Cypre Inc. All rights reserved.
Privacy Policy
Terms of Service